Markets
Upside down house
So this is a story all about how our markets got flipped upside down (Juancho Torres/Getty Images)
Internal agony

Boring stocks are the only reason the S&P 500 is up in August, and that’s a little scary

So-called low volatility stocks are up a lot while more volatile ones are down. This is not the usual state of affairs.

Luke Kawa

After a rollercoaster ride, the S&P 500 is up about 2.5% over its past 21 days (roughly equivalent to one month in trading time).

But what’s unusual is which stocks have risen and which have gone down.

So-called high beta stocks — those that are supposed to move more than the market does — are slightly lower over this period, with low volatility stocks posting strong gains.

This is not the usual state of affairs. Typically, stocks go up and high beta stocks do better than their low volatility peers.

High beta stocks are categorized as high beta stocks because they tend to behave like the S&P 500 on steroids: the market goes up, they go up by more, and vice versa.

The opposite for low volatility stocks, which are typically the “a little bit softer now” version of the overall market.

If we look just at periods when the S&P 500 is up 1% over a month, only 6% of the time high beta stocks are doing worse versus low vol stocks than we've recently seen.

This odd dynamic may be a function of the unusual market conditions: the sharp decline and furious bounce back. High beta stocks far underperformed on the way down in early August, and have since meaningfully outperformed on the rebound.

In this light, it could reflect timid investors amid still-unresolved jitters on the state of the economy that have been only partially soothed by the high visibility into rate cuts from the Federal Reserve coming soon.

Conversely, you could come to the exact opposite conclusion. Chipmakers are very well-represented in the high-beta stock index at present, and those were a very popular trade that came under outsized pressure during what seemed to be a more technical than economically-driven market tumult.

A market led by low vol has some less-than-stellar implications for near-term returns, though is by no means a harbinger of doom.

The median forward 21-session return for the S&P 500 following periods in which low volatility stocks are meaningfully outperforming high beta stocks during a market rally is 0.8% (versus a 1.2% median monthly increase for the S&P 500).

The skew is also less favorable: for all periods, the 25th percentile 21-day rolling return for the S&P 500 is -1.4% and the 75th percentile return is +3.4%. After low vol-led rallies, the 25th percentile return is -2% and the 75th percentile return is 2.5%.

More Markets

See all Markets
markets

Nike pops on Q1 earnings beat and surprise revenue jump

Nike topped first-quarter estimates after the bell Tuesday.

Adjusted earnings per share came in at $0.49, nearly double the $0.27 expected by Wall Street. Revenue rose to $11.7 billion, also beating analyst forecasts of $11 billion. Wholesale revenues rose 7% to $6.8 billion.

On Friday, the sneaker giant rolled out its first collaboration with Kim Kardashian’s Skims, betting that the brand’s popularity and star power will help expand its female customer base.

Ahead of earnings, Nike shares were down over 5% year to date.

markets

Betting stocks slammed on growing pressure from prediction markets

The duopoly that dominates the US online sports betting business — DraftKings and FanDuel parent Flutter Entertainment — dove Tuesday after prediction markets company Kalshi quietly introduced a new feature mimicking the popular parlay-style sports bets that have been an important differentiator for the sportsbooks from fast-growing prediction markets.

Robinhood Markets, which has partnered with prediction markets platform Kalshi to offer event contracts to its users, has surged to record highs in recent days on signs that its prediction markets business is gaining traction as the NFL season unfolds.

(Robinhood Markets Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Market analysts have noted that prediction markets — which in the US are regulated as financial products by the CFTC — have some significant regulatory advantages compared to non-prediction market sports betting activity, which typically operates under state gaming regulators.

“Prediction markets like Kalshi, which is available nationwide to anyone over 18, are... increasingly an alternative to traditional online sportsbooks like DraftKings, which is generally available 21 and up in about half the country,” analyst Edwin Dorsey wrote earlier this month on his newsletter The Bear Cave, which spotlights potential short positions on some stocks.

Separately, Flutter is also under some idiosyncratic pressure amid reports that Rachel Reeves, the UK’s chancellor of the exchequer, is open to raising taxes on the country’s gambling companies in the upcoming budget.

markets

Nio climbs following a more than 60% jump in weekly registrations in China

A host of new Model Y competitors appear to be paying off for Chinese EV maker Nio.

Shares of the company rose more than 5% in Tuesday morning trading, following reports that the company last week logged a record 10,800 vehicle insurance registrations in China, a common proxy for vehicle deliveries.

The figure, which would represent a 62% jump in registrations week over week, was reportedly shared by a Nio executive on Chinese social media. Nio is said to have delivered more than 2,000 of its new three-row electric SUV, the ES8, and 2,600 Onvo L90s (another SUV) in the week ended September 28.

markets

Pfizer reaches deal with Trump admin on drug pricing

Pfizer rose Tuesday after it was announced that the drugmaker reached a deal with the Trump administration to lower its prices in the US.

Pfizer will sell its drugs through Medicaid at lower prices, according to the White House. In its own press release, Pfizer said it has agreed to take steps to ensure Americans receive comparable drug prices to those available in other developed countries and will price newly launched medicines at parity with other key developed markets.

Pfizer said it would participate in the administrations direct-to-consumer platform dubbed “TrumpRx. Many of the companys drugs will be available on TrumpRx.gov (the website does not appear to be active yet) at at savings that will range as high as 85% and on average 50%.

The specific terms of the agreement are confidential, Pfizer said. President Trump signed an executive order in May demanding drugmakers give the US the best prices on medications, and the deadline to comply with that was Monday.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.